

## Requirement of STE50 for Osmostress-Induced Activation of the STE11 Mitogen-Activated Protein Kinase Kinase Kinase in the High-Osmolarity Glycerol Response Pathway

FRANCESC POSAS, ELIZABETH A. WITTEN, AND HARUO SAITO\*

*Dana-Farber Cancer Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115*

Received 5 June 1998/Returned for modification 9 July 1998/Accepted 13 July 1998

**Exposure of yeast cells to increases in extracellular osmolarity activates the HOG1 mitogen-activated protein (MAP) kinase cascade, which is composed of three tiers of protein kinases: (i) the SSK2, SSK22, and STE11 MAP kinase kinases (MAPKKKs), (ii) the PBS2 MAPKK, and (iii) the HOG1 MAP kinase. Activation of the MAP kinase cascade is mediated by two upstream mechanisms. The SLN1-YPD1-SSK1 two-component osmosensor activates the SSK2 and SSK22 MAPKKKs by direct interaction of the SSK1 response regulator with these MAPKKKs. The second mechanism of HOG1 MAP kinase activation is independent of the two-component osmosensor and involves the SHO1 transmembrane protein and the STE11 MAPKKK. Only PBS2 and HOG1 are common to the two mechanisms. We conducted an exhaustive mutant screening to identify additional elements required for activation of STE11 by osmotic stress. We found that strains with mutations in the *STE50* gene, in combination with *ssk2Δ ssk22Δ* mutations, were unable to induce HOG1 phosphorylation after osmotic stress. Both two-hybrid analyses and coprecipitation assays demonstrated that the N-terminal domain of STE50 binds strongly to the N-terminal domain of STE11. The binding of STE50 to STE11 is constitutive and is not affected by osmotic stress. Furthermore, the two proteins relocate similarly after osmotic shock. It was concluded that STE50 fulfills an essential role in the activation of the high-osmolarity glycerol response pathway by acting as an integral subunit of the STE11 MAPKKK.**

Mitogen-activated protein (MAP) kinase cascades are common signaling modules found in both higher and lower eukaryotic cells. A typical MAP kinase cascade is composed of three tiers of protein kinases, a MAP kinase (MAPK), a MAPK kinase (MAPKK), and a MAPKK kinase (MAPKKK) (27). Yeast cells have several distinct MAP kinase cascades that transduce distinct extracellular stimuli (e.g., mating pheromone, high osmolarity, low osmolarity, and nitrogen starvation) (10, 19). Budding yeast (*Saccharomyces cerevisiae*) responds to increases in osmolarity in the extracellular environment by activating the HOG1 MAP kinase cascade. This cascade is essential for the survival of yeast in high-osmolarity environments (4, 5). Because a major outcome of the activation of this MAPK pathway is the elevated synthesis of glycerol, this pathway is referred to as the HOG (high-osmolarity glycerol response) pathway (2, 5). Extracellular hyperosmolarity is detected by either of two transmembrane proteins, SLN1 and SHO1 (Fig. 1).

SLN1 is a part of a complex regulatory system with homology to prokaryotic two-component signal transducers. The yeast two-component osmosensor is composed of SLN1, a transmembrane protein that contains an extracellular sensor domain and cytoplasmic histidine kinase and receiver domains, the intermediary protein YPD1, and the response regulator SSK1 (14, 15, 20). The SLN1-YPD1-SSK1 two-component osmosensor works by a multistep phosphorelay mechanism (20). The unphosphorylated form of SSK1 activates SSK2 and SSK22 MAPKKKs by binding to their N-terminal inhibitory domains (17). Once activated, SSK2 and SSK22 phosphorylate the PBS2 MAPKK.

However, the SLN1-YPD1-SSK1 multistep phosphorelay is not the only osmosensing mechanism in yeast. Initially, this was revealed because, unlike highly osmosensitive *hog1Δ* or *pbs2Δ* mutants, neither *ssk1Δ* mutants nor *ssk2Δ ssk22Δ* double mutants exhibited the expected osmosensitive phenotype. Thus, we conducted a mutant screening based on the assumption that simultaneous inactivation of *SSK2*, *SSK22*, and a gene involved in the alternative activation mechanism would create an osmosensitive (*Osm<sup>s</sup>*) phenotype. Briefly, *ssk2Δ ssk22Δ* double mutants were mutagenized, and *Osm<sup>s</sup>* mutants were selected. This screening identified two genes (*SHO1* and *STE11*) whose mutations were synthetically *Osm<sup>s</sup>* with *ssk2 ssk22*. *SHO1* has four predicted transmembrane segments and a C-terminal cytoplasmic region that contains an SH3 domain. The SH3 domain binds a proline-rich motif in the N-terminal segment of the PBS2 MAPKK. This interaction is a requirement for the activation of the PBS2 MAPKK by the STE11 MAPKKK (13, 16). Thus, PBS2 can be independently activated by two different upstream mechanisms: one involving the SLN1-YPD1-SSK1 two-component osmosensor that activates SSK2 and SSK22 MAPKKKs, and another involving the SHO1 transmembrane protein and the STE11 MAPKKK. Either SSK2, SSK22, or STE11 MAPKKK can activate PBS2 by phosphorylation. Once phosphorylated, PBS2 MAPKK activates the HOG1 MAPK, which induces diverse stress responses.

The mechanism by which SHO1 induces activation of STE11 is not clear. In particular, there remained the possibility that additional elements were required for signal transduction in the SHO1-STE11 branch of the HOG pathway. Therefore, we expanded the synthetic osmosensitive mutant screening to apparent saturation. Thus, we found that in addition to the previously revealed *SHO1* and *STE11* genes, the *STE50* gene is involved in the HOG pathway. Although STE50 was originally identified as a modulator of the pheromone response pathway,

\* Corresponding author. Mailing address: Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115. Phone: (617) 632-3814. Fax: (617) 632-4569. E-mail: haruo\_saito@dfci.harvard.edu.




FIG. 1. Schematic diagram of a current model of the yeast HOG osmoregulatory signal transduction pathway. The arrows do not necessarily indicate direct interactions.

*ste50* mutations had only moderate effects on mating signal transduction (21, 28). In contrast, we demonstrate in this report that STE50 is absolutely required for the SHO1-STE11-mediated activation of the HOG pathway.

#### MATERIALS AND METHODS

**Yeast strains.** The yeast strains used were FP54 (*MATa ura3 leu2 trp1 his3 ste11::HIS3*), FP66 (*MATa ura3 leu2 trp1 his3 ste50::HIS3*), FP67 (*MAT $\alpha$  ura3 leu2 trp1 his3 ssk2::LEU2 ssk22::LEU2 ste50::HIS3*), FP68 (*MAT $\alpha$  ura3 leu2 trp1 his3 sho1::TRP1 ste50::HIS3*), FP75 (*MAT $\alpha$  ura3 leu2 trp1 his3 ssk2::LEU2 ssk22::LEU2 ste11::HIS3*), L40 (*MATa trp1 leu2 his3 LYS2::lexA-HIS3 URA3::lexA-lacZ*), MY007 (*MATa ura3 leu2 his3 ssk2::LEU2 ssk22::LEU2 sho1::HIS3*), TM101 (*MAT $\alpha$  ura3 leu2 his3*), TM141 (*MATa ura3 leu2 trp1 his3*), TM252 (*MATa ura3 leu2 trp1 ssk2::LEU2 ssk22::LEU2*), TM257 (*MAT $\alpha$  ura3 leu2 trp1 his3 ssk2::LEU2 ssk22::LEU2*), and TM261 (*MAT $\alpha$  ura3 leu2 his3 pbs2::LEU2*).

**Buffers and media.** Tris-maleate buffer contains 50 mM Tris base, 50 mM maleic acid, 7.5 mM ammonium acetate, 0.4 mM  $MgSO_4$  and 30 mM  $CaCl_2$  (adjusted to pH 6.0 with NaOH). Buffer A consists of 50 mM Tris-HCl (pH 7.5), 15 mM EDTA, 15 mM EDTA, 2 mM dithiothreitol (DTT), 0.1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, and 5  $\mu$ g of leupeptin per ml. Buffer B consists of 50 mM Tris-HCl (pH 7.5), 10 mM  $MgCl_2$ , and 2 mM DTT. Phosphatase inhibitor cocktail consists of 10 mM NaF, 1 mM sodium pyrophosphate, 1 mM sodium vanadate, and 10 mM  $\beta$ -glycerol phosphate. Sodium dodecyl sulfate (SDS) loading buffer consists of 50 mM Tris-HCl (pH 6.8), 100 mM DTT, 2% SDS, 0.1% bromophenol blue, and 10% glycerol. YPD medium contains 10 g of yeast extract, 20 g of tryptone, and 20 g of dextrose per liter. YPGal medium contains 10 g of yeast extract, 20 g of tryptone, and 20 g of galactose per liter.

**Isolation of osmosensitive mutants.** Yeast strain TM252 (*ssk2 $\Delta$  ssk22 $\Delta$* ) was mutagenized with *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG) as follows. TM252 cells were grown in YPD at 30°C to an optical density at 600 nm of 0.3, washed twice in Tris-maleate buffer (pH 6.0), and resuspended in 1/5 of the original volume in the same washing buffer (1). Thirty microliters of 1-mg/ml MNNG solution in 10 mM sodium acetate buffer (pH 5.0) was added to 970  $\mu$ l of yeast cell suspension in a microcentrifuge tube, and the mixture was incubated at 30°C for 60 min. Cells were sedimented by a brief centrifugation and resuspended in 1 ml of 1% sodium thiosulfate solution (sterilized by filtration). After another centrifugation, cell pellets were resuspended in 5 ml of YPD and incubated at 30°C for 4 h. Glycerol was added to a final concentration of 30%, and aliquots were stored frozen at -80°C. Mutagenized cells were plated on YPD plates (~500 colonies/plate). After incubation at 30°C for 2 to 3 days, colonies were replica plated onto YPD-1.5 M sorbitol plates. Both the master plates and replica plates were incubated at 30°C for another day or two. Mutants that failed to grow on sorbitol plates were recovered from the master plates. Single colonies were isolated and tested for osmosensitivity on sorbitol plates.

**Plasmids.** The yeast expression vector YCpIF16 ( $P_{GAL1}$ -hemagglutinin [HA] *TRP1*<sup>+</sup> CEN) allows the expression of HA fusion proteins under control of the *GAL1* promoter (9), and p426TEG1 ( $P_{TEF1}$ -glutathione *S*-transferase [GST], *URA3*<sup>+</sup> 2 $\mu$ m) allows the expression of GST fusion proteins under control of the  $P_{TEF1}$  promoter (24). Full-length and several mutant alleles of *STE50* and *STE11* were cloned into plasmids YCpIF16 and p426TEG1. Plasmid vectors for green fluorescent protein (GFP) tag (pJK50) and Myc<sub>3</sub> tag (p1148) were obtained from P. Silver. The tag sequences amplified by PCR were subcloned into pRS416

(*URA3*<sup>+</sup> CEN) and pRS415 (*TRP1*<sup>+</sup> CEN) (23). A *STE11*<sup>STE50BD</sup> mutant containing a deletion of the STE50 binding domain (STE50DBD; amino acids 74 to 152) was made by PCR and verified by DNA sequencing. Yeast expression plasmids for full-length STE50, the N terminus of STE50 (STE50-N; amino acids 1 to 166), and the C terminus of STE50 (STE50-C; amino acids 163 to 346) were constructed by using pYES2 ( $P_{GAL1}$  *URA3*<sup>+</sup> 2 $\mu$ m) (Invitrogen).

**Quantitative mating assay.** Cells were grown at 30°C to mid-exponential phase. Mutant strains to be tested (*MATa*) were mixed with a fourfold excess of an appropriate tester strain (*MAT $\alpha$* ) and immediately filtered through nitrocellulose membranes. The membranes were placed on YPD plates and incubated at 30°C for 4 h to allow mating to proceed. The cells were then washed off the membranes and titrated on selective plates to determine the number of diploid cells formed. Mating efficiency was defined as the number of diploid cells formed divided by the number of experimental (*MATa*) haploid cells.

**Two-hybrid analysis.** The two-hybrid analysis was carried out essentially as described by Durfee et al. (6), using pACTII (11) and pBTM116 (26) as the activation domain plasmid and the LexA DNA binding domain plasmid, respectively. Serial deletion constructs of STE11 and STE50 were prepared by using the Erase-a-Base system (Promega), PCR techniques, and standard DNA procedures. Binding domain plasmids carrying full-length or fragments of STE11 and pACTII plasmids carrying full-length or partial clones of STE50 were cotransformed into the L40 reporter strain. Transformant cells (~5 × 10<sup>6</sup>) were spotted onto a YPD plate, and after 5 h at 30°C the cells were copied onto a nitrocellulose membrane.  $\beta$ -Galactosidase activity was visualized with the use of 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-Gal) as described elsewhere (26).

**In vivo coprecipitation assays.** Cells were grown in the presence of 2% galactose to an optical density at 660 nm of ~0.5. Cells were treated with a brief osmotic shock (0.4 M NaCl for 5 min) before being harvested by centrifugation. Cells were suspended in buffer A and ground by using glass beads, and supernatant (extract) was prepared by centrifugation. Cell extract (750  $\mu$ g in buffer A plus 150 mM NaCl) was incubated with 50  $\mu$ l of glutathione-Sepharose beads overnight at 4°C. Beads were washed extensively with buffer A plus 150 mM NaCl, resuspended in loading buffer, and separated by SDS-polyacrylamide gel electrophoresis. Immunoblotting was done with anti-HA monoclonal antibody 12CA5 (Boehringer Mannheim) and an anti-GST monoclonal antibody (Pharmacia) together with ECL reagent (Amersham). When GFP- and Myc<sub>3</sub>-tagged STE11 (STE11-GFP and STE50-Myc) were coprecipitated, cells were grown in presence of glucose. Extracts were prepared as before, and STE11-GFP was precipitated by incubation overnight at 4°C with an anti-GFP polyclonal antibody (gift from P. Silver), followed by addition of 50  $\mu$ l of protein A-Sepharose (Pharmacia) for 1 h at 4°C. Samples were washed with buffer A plus 150 mM NaCl. Following SDS-polyacrylamide gel electrophoresis, immunoblotting was done with anti-Myc monoclonal antibody 9E10 (BabCO) or an anti-GFP polyclonal antibody.

**GFP fluorescence microscopy.** GFP was visualized without fixation using a Nikon Optiphot-2 equipped with a MicroMAX charge-coupled device (CCD) camera (Princeton Instruments). Images were taken at a magnification of 100 $\times$  and converted to Photoshop version 4.0 format (Adobe Systems).

#### RESULTS

**Identification of additional elements required for SSK2/SSK22-independent activation of the HOG1 MAP kinase cascade.** As mentioned in the introduction, *ssk1 $\Delta$*  or *ssk2 $\Delta$  ssk22 $\Delta$*  strains are osmoresistant, whereas *pbs2 $\Delta$*  strains are highly osmosensitive. This would not be expected if SSK1 (the activator of SSK2/SSK22) and SSK2/SSK22 MAPKKKs are the only means of activating PBS2. Thus, it was predicted that there is an SSK2/SSK22-independent mechanism that can activate PBS2 upon osmotic shock. To identify the elements involved in the alternative osmosensing mechanism, we conducted a mutant screening by which we isolated osmosensitive mutants from a *ssk2 $\Delta$  ssk22 $\Delta$*  double-mutant strain (13, 16). We identified two genes, those encoding the STE11 MAPKKK and the novel transmembrane protein SHO1, mutations of which, combined with the *ssk2 $\Delta$  ssk22 $\Delta$*  double mutation, causes an Osm<sup>s</sup> phenotype. It has been shown that STE11 can activate PBS2 MAPKK both in vivo and in vitro. It was also shown that the C-terminal SH3 domain of SHO1 binds PBS2. However, the mutant screening was probably not saturated, because only one mutant for each of *SHO1* and *STE11* was isolated.

Thus, to identify additional elements required for the SHO1-STE11 branch of the HOG pathway, an exhaustive screening was performed. The *ssk2 $\Delta$  ssk22 $\Delta$*  strain TM252 was mutagenized with MNNG as described in Materials and Methods;

TABLE 1. Summary of a screening for osmosensitive mutants

Complementation group	No. of mutants/140 cells screened
<i>hog1</i> .....	17
<i>pbs2</i> .....	34
<i>sho1</i> .....	7
<i>ste11</i> .....	7
<i>ste50</i> .....	3
<i>gpd1</i> .....	10
<i>X</i> .....	17
<i>tat1</i> .....	4
Unclassified mutants.....	41

<sup>a</sup> Yeast strain TM252 (*ssk2Δ ssk22Δ*) was mutagenized with MNNG as described in Materials and Methods. Mutagenized cells were grown on YPD plates and replica plated onto YPD-1.5 M sorbitol plates. Mutant cells that failed to grow on sorbitol-containing plates were isolated and classified into complementation groups. Mutants in the *gpd1*, *X*, and *tat1* complementation groups, as well as the 41 unclassified mutants, were not defective in the hyperosmolarity-induced activation of the HOG1 MAPK and were not characterized further.

then 200,000 mutagenized cells were grown on YPD plates and replicated onto YPD plates containing 1.5 M sorbitol. By comparing the master and the replica plates, we identified Osm<sup>s</sup> colonies. After single-colony isolation, those candidate mutants were tested again for osmosensitivity (i.e., inability to grow on YPD-sorbitol plates). Thus, 140 Osm<sup>s</sup> mutants were identified. In the next step, we identified the mutants of the already identified genes, namely *hog1*, *pbs2*, and *sho1*, by complementation analysis. As summarized in Table 1, we obtained numerous strains with mutations of these three genes. *STE11* mutants could not be directly tested by the complementation test, as they were sterile. However, these mutants could be identified by their sterility in the mating test and by subsequent complementation by an *STE11*-containing plasmid (Table 1). The seven sterile mutants isolated in this screening were defective in the *STE11* gene.

The remaining Osm<sup>s</sup> mutants contained a number of distinct complementation groups. Of those, the largest number of mutants belonged to an unknown gene (*X*). Two additional complementation groups were identified as *gpd1* and *tat1* mutants, by complementation cloning. The *GPD1* gene encodes glycerol-3-phosphate dehydrogenase, a key enzyme for the synthesis of the compatible osmolyte glycerol (2). The *TAT1* gene encodes a valine/tyrosine/tryptophan permease; it is likely that these amino acids also act as compatible osmolytes that maintain the osmotic balance (22). *X*, *GPD1*, and *TAT1* mutants do not affect the activation of the HOG1 MAPK, because immunoblot analysis of these mutants demonstrated that the HOG1 tyrosine phosphorylation (an indicator of the HOG1 activation) occurred as efficiently as in wild-type cells. Thus, these genes may be important for yeast osmoregulation but not in the activation of the HOG1 MAP kinase cascade itself. To identify mutations that are defective in HOG1 activation among the remaining mutants, we tested individual Osm<sup>s</sup> mutants by immunoblot analysis to see if they are capable of inducing HOG1 tyrosine phosphorylation after osmotic stress. Thus, we found three additional mutants (FOS-41, FOS-174, and FOS-226) that are defective in HOG1 phosphorylation. We isolated the genes that are responsible for their osmosensitivity by complementation using a genomic library. Characterization of the complementing genomic clones by mapping and partial sequencing revealed that they contained either the *SSK2*, *SSK22*, or *STE50* gene. Figure 2A shows that the osmosensitivity of FOS-41 can be complemented by either *SSK2*, *SSK22*, or *STE50* carried on a single-copy vector. Essentially

identical results were obtained for FOS-174 and FOS-226. The *STE50* gene, which encodes a protein of 346 amino acids, was previously implicated in the pheromone response pathway (21, 28).

#### Synthetic osmosensitivity of *ste50 ssk2 ssk22* triple mutants.

To exclude the possibility that *STE50* was merely acting as a multicopy suppressor of FOS-41 and the other two mutants, we generated a disruption mutation of *STE50* in an *ssk2Δ ssk22Δ* background. The *ssk2Δ ssk22Δ ste50Δ* strain (FP67) was as osmosensitive as FOS-41 (data not shown), indicating that it is very likely that FOS-41 is defective in the *STE50* gene. However, because none of the three suspected *ste50* mutants were mating defective, we used a *ste50Δ* strain to reinvestigate the involvement of *STE50* in the mating pathway. As shown in Table 2, *ste50Δ* cells showed only a slight decrease in mating efficiency when mated with an isogenic wild-type strain. Mating deficiency was more severe when both partners were *ste50* deficient (but not as defective as the *ste11* mutant). Thus, these results are consistent with the apparent mating competence of FOS-41 and the other two mutants. Furthermore, these results confirm that the role of *STE50* in the mating pathway is a




FIG. 2. Activation of the HOG1 MAPK by SHO1 requires STE50. (A) Osmosensitivity of FOS-41 (*ssk2Δ ssk22Δ ste50-41*). FOS-41 was transformed with centromeric plasmids containing the indicated genes. The transformants were spotted on YPD plates with or without 1.5 M sorbitol. (B) Tyrosine phosphorylation of HOG1 induced by high osmolarity. Yeast strain FP67 (*ssk2Δ ssk22Δ ste50Δ*) was transformed with plasmids carrying the indicated genes. Cells were collected before (–) or 5 min after (+) the addition of NaCl to a final concentration of 0.4 M. Tyrosine-phosphorylated HOG1 (Hog1p) was detected by immunoblot analysis using a monoclonal antibody specific to phosphotyrosine (4G10). (C) High-osmolarity-induced tyrosine phosphorylation of HOG1 in various mutant strains. Cells were treated, and tyrosine-phosphorylated HOG1 (Hog1p) was detected as for panel B. (D) Tyrosine phosphorylation of HOG1 induced by the constitutively active *STE11ΔN*. Plasmid pGal-*STE11ΔN* was transformed into wild-type (WT), *ste50Δ*, and *pbs2Δ* strains. Cells were grown in synthetic medium containing raffinose, and samples were taken before (–) or 1 h after (+) addition of galactose to induce the expression of *STE11ΔN*. Tyrosine-phosphorylated HOG1 (Hog1p) was detected by immunoblotting.

TABLE 2. Mating efficiencies

Relevant genotype		Mating efficiency (%) <sup>a</sup>
<i>MAT</i> <sub>a</sub> strain	<i>MAT</i> <sub>α</sub> strain	
Wild type	Wild type	90.3 ± 2.4
<i>ste11Δ</i>	Wild type	<0.0001
<i>ste50Δ</i>	Wild type	34.7 ± 6.1
<i>ste50Δ</i>	<i>ste50Δ</i>	0.8 ± 0.2

<sup>a</sup> Determined by mixing exponentially growing *MAT*<sub>a</sub> cells with a fourfold excess of *MAT*<sub>α</sub> cells (see Materials and Methods) and calculated as [(number of diploid cells formed)/(number of *MAT*<sub>a</sub> cells)] × 100. Data represents means ± standard deviations of results from three independent experiments.

modulatory one rather than essential, as previously suggested (21, 28).

The *ssk2Δ ssk22Δ ste50Δ* triple mutant has completely lost the capacity to activate the HOG pathway, as indicated by its inability to tyrosine phosphorylate HOG1 after osmotic stress (Fig. 2B and C). Transformation of the triple-mutant strain with a plasmid carrying either *SSK2*, *SSK22*, or *STE50* restored HOG1 activation in response to osmotic shock, whereas expression of *SHO1*, *STE11*, *PBS2*, or *HOG1* had no apparent effect (Fig. 2B). Any of the three mutations, *sho1Δ*, *ste11Δ*, or *ste50Δ*, when combined with the *ssk2Δ ssk22Δ* double mutation, disabled the activation of HOG1 upon osmotic shock (Fig. 2C). In a *sho1Δ ste50Δ* double mutant, in which both *SSK2* and *SSK22* are functional, HOG1 activation in response to osmotic shock was normal (Fig. 2C). Similarly, *sho1Δ ste11Δ* double mutants were osmosensitive and capable of activating HOG1 (16). These results suggest that *SHO1*, *STE11*, and *STE50* are involved in the same upstream branch (the *SHO1*-*STE11* branch) of the HOG pathway.

We then tested whether *STE50* is required for *STE11* to phosphorylate its substrate *PBS2* (for example, *STE50* might modulate *STE11* affinity to *PBS2*). If this is the case, it would be expected that *STE50* is required for *PBS2* phosphorylation even by a constitutively active mutant form of *STE11* (*STE11ΔN*). As previously observed (16), expression of *STE11ΔN* resulted in *PBS2*-mediated tyrosine phosphorylation of HOG1 in the absence of osmotic stress (Fig. 2D). Significantly, *STE11ΔN* could induce HOG1 phosphorylation in a *ste50Δ* strain, indicating that *STE50* is not required for the active *STE11* to phosphorylate *PBS2*. It is therefore more likely that *STE50* acts upstream of *STE11*.

**STE50 interacts with STE11 MAPKKK but not with SHO1.** *STE50* has some structural similarities to the *Schizosaccharomyces pombe* *Ste4* protein, which has also been implicated in the mating pathway. *Ste4* interacts with the N-terminal non-catalytic domain of the *Byr2* MAPKKK (a homolog of *STE11*) (3, 25). It has also been suggested by two-hybrid analysis that *STE50* interacts with *STE11* (3, 28). To examine whether *STE50* was able to interact with *STE11* and other components in the *SHO1*-*STE11* branch of the HOG pathway, we performed coprecipitation experiments. Yeast cells were cotransformed with a plasmid that expresses either GST-*SHO1* or GST-*STE11* and another plasmid that expresses HA-*STE50*. GST-tagged proteins were precipitated by using glutathione-Sepharose beads, and HA-*STE50* in precipitates was probed with an anti-HA monoclonal antibody. As shown in Fig. 3, GST-*STE11*, but not GST alone or GST-*SHO1*, coprecipitated HA-*STE50*. The *STE11* N-terminal noncatalytic domain alone (GST-*STE11*-N; amino acids 1 to 434) also coprecipitated amounts of HA-*STE50* equivalent to those of the full-length *STE11*. The binding of *STE11* to *STE50* was also observed in *sho1Δ* and *pbs2Δ* backgrounds, indicating that neither *SHO1*

nor *PBS2* was required as a bridge between *STE11* and *STE50* (data not shown). Thus, *STE50* interacts with *STE11*, within the N-terminal regulatory domain of *STE11*.

**STE50-N binds to STE50 binding site in the N-terminal domain of STE11.** To define the specific regions in *STE50* and *STE11* that are essential for their interaction, two-hybrid analyses were carried out. To map the *STE50* binding site in *STE11*, various segments of *STE11* were fused to the LexA-DNA binding domain, and their interaction with the full-length *STE50* fused to the GAL4 activator domain was tested. Figure 4A shows a typical result, and Fig. 4B summarizes the results for various *STE11* deletion constructs. These analyses indicated that *STE11* residues 85 to 137 are sufficient for binding to *STE50*, consistent with the coprecipitation experiments. We thus designated this segment *STE50BD*.

To determine the region in *STE50* that is essential for its interaction with the N-terminal domain of *STE11*, we fused various *STE50* segments to the GAL4 activation domain and tested these constructs for interaction with the full-length *STE11* fused to the LexA-DNA binding domain. As shown in Fig. 5, an N-terminal segment of *STE50* (amino acids 68 to 118) is necessary and sufficient for binding to *STE11*.

The conclusion from these two-hybrid analyses were confirmed by in vivo coprecipitation experiments. Yeast cells were cotransformed with a plasmid that expresses GST-*STE11* or GST-*STE11*<sup>ΔSTE50BD</sup> and HA-*STE50* or HA-*STE50*-N. Both HA-*STE50* and HA-*STE50*-N bound to GST-*STE11* but not to GST-*STE11*<sup>ΔSTE50BD</sup> (Fig. 6). No interaction was observed between *STE50*-C and GST-*STE11* (data not shown). Thus, these in vivo binding assays confirmed the conclusion of the two-hybrid analyses.

**STE50 binding is essential for STE11 activation by osmotic stress.** We examine whether *STE50* binding to *STE11* is necessary for its activation of the HOG pathway under osmotic stresses. For this purpose, we compared wild-type *STE11* and the *STE11*<sup>ΔSTE50BD</sup> mutant allele for the ability to complement the osmosensitivity of the *ssk2Δ ssk22Δ ste11Δ* strain (FP75). As shown in Fig. 7A, wild-type *STE11* restored growth




FIG. 3. In vivo binding of *STE50* to *STE11*. Wild-type yeast strain TM141 was cotransformed with a plasmid expressing GST, GST-*STE11*, GST-*STE11*-N, or GST-*SHO1* and another plasmid expressing HA-*STE50*. GST proteins were precipitated by using glutathione-Sepharose beads, and the presence of HA-*STE50* in precipitates was probed by immunoblotting with anti-HA monoclonal antibody 12CA5 (upper panel). GST fusion proteins in the precipitates were detected by an anti-GST antibody (lower panel).




FIG. 4. Two-hybrid analysis of the STE50-binding domain in STE11. (A) Interactions of various STE11 fragments fused to the LexA-DNA binding domain with the STE50 fragments fused to the GAL4 activator domain. The results, representative of several filter  $\beta$ -galactosidase assays, demonstrate the interactions between STE11 and STE50. Amino acid positions of the STE11 fragments included in the constructs are indicated in parentheses. pACT-STE50 contains the entire *STE50* coding sequence. Proteins encoded by the control plasmids pLexA-RAS<sup>VAL12</sup> and pACT-RAF interact with each other (26). (B) Summary of two-hybrid interaction between STE11 and STE50. Positions of the STE11 segments included in the LexA-DNA binding domain are schematically shown on the left, and their precise amino acid positions are indicated on the right. The presence (+) or absence (-) of interaction is indicated.

of FP75 on sorbitol medium whereas *STE11*<sup>ΔSTE50BD</sup> did not, suggesting that binding of STE50 to STE11 is essential for activation of the HOC pathway. The *STE11*<sup>ΔSTE50BD</sup> mutant is also mating deficient (data not shown). This appears to be, at least partly, due to a partial overlap between the STE50 and STE5 binding domains in STE11 (18).

We then tested if occupancy of the STE50BD in STE11 was sufficient to allow activation of STE11 under osmotic stress. For this purpose, we examined whether expression of STE50-N, which spans the STE11 binding site, could suppress the osmosensitivity of the *ssk2Δ ssk22Δ ste50Δ* strain (FP67). As shown in Fig. 7B, expression of neither STE50-N nor STE50-C alone was able to complement the *ste50Δ* deficiency. Thus, even though the N terminus of STE50 is sufficient for binding to STE11 (Fig. 5 and 6), it is not enough to activate STE11 under osmotic stress.

**STE50 is constitutively associated with STE11.** A molecular mechanism to activate MAPKKs is binding of upstream regulators to N-terminal regulatory regions in MAPKKs. For example, binding of the SSK1 response regulator to SSK2 MAPKK induces its kinase activity (17). Thus, a possible role of STE50 is to bind and activate STE11 upon osmotic shock. If this hypothesis is correct, the binding of STE50 to STE11 probably depends on extracellular osmotic conditions. To test this possibility, yeast cells were cotransformed with expression plasmids for GST-STE50 (or GST alone) and HA-STE11. Cells were untreated or treated with a brief osmotic shock before lysis, and the presence of HA-STE11 in the GST-STE50




FIG. 5. Two-hybrid analysis of the STE11BD in STE50. (A) Interactions of various STE50 fragments fused to the GAL4 activator domain with STE11 fused to the LexA-DNA binding domain. The pLexA-STE11 construct contains the entire *STE11* coding sequence. Amino acid positions of the *STE50* fragments included in the constructs are indicated in parentheses. (B) Summary of the two-hybrid interaction analysis between STE50 and STE11. Positions of the STE50 segments included in the activator domain constructs are schematically shown on the left, and their precise amino acid positions are indicated on the right side. The presence (+) or absence (-) of interaction is indicated.

precipitate was probed. As shown in Fig. 8A, HA-STE11 was precipitated with STE50 equally well when the cells were treated with osmotic shock and when they were not. The same results were obtained when the order of precipitation was reversed, using GST-STE11 and HA-STE50 (data not shown).

The above experiments were performed with the strong *GALI*




FIG. 6. In vivo binding of STE50-N to the STE50BD in STE11. Wild-type yeast strain TM141 was cotransformed with a plasmid expressing GST, GST-STE11, or GST-STE11<sup>ΔSTE50BD</sup> (deletion mutant lacking amino acids 74 to 152) and another plasmid expressing HA-STE50 or HA-STE50-N. GST proteins were precipitated by using glutathione-Sepharose beads, and HA-STE50 in precipitates (lanes 1 to 3) or HA-STE50-N (lanes 4 and 5) was probed by immunoblotting with anti-HA monoclonal antibody 12CA5 (upper panel). An antibody against GST was used to detect the GST fusion proteins (lower panel). The GST band in lane 1 is not shown to save space (see Fig. 3).




FIG. 7. Expression of STE11 and STE50 mutant alleles in the respective deficient strains. (A) Complementation of the FP75 (*ssk2Δ ssk22Δ ste11Δ*) osmosensitivity by expression of the wild-type *STE11* but not the *STE11*<sup>ΔSTE50BD</sup> allele. Host cells were transformed with plasmids that express the indicated *STE11* alleles expressed under the constitutive *P<sub>TEF1</sub>* promoter. The transformants were spotted on YPD plates with or without 1.5 M sorbitol. (B) The following segments of STE50 were expressed under the *P<sub>GAL1</sub>* promoter: pGal-STE50 (full-length STE50; amino acids 1 to 346), pGal-STE50-N (amino acids 1 to 166), and pGal-STE50-C (amino acids 165 to 346). Plasmids were transformed into the host, and the transformants were spotted on YPGal plate with or without 1.5 M sorbitol.

promoter. Because the amounts of STE11 and STE50 proteins in those experiments are much higher than under physiological conditions, we repeated the STE11-STE50 binding test in an assay using a centromeric (low-copy-number) plasmid vector and the native promoters of STE11 and STE50. STE11 was

fused to GFP (STE11-GFP), and STE50 was fused to a Myc<sub>3</sub> tag (STE50-Myc). Both STE11-GFP and STE50-Myc were functional, because their expression complemented the osmosensitive defects of *ste11Δ* and *ste50Δ* mutations, respectively (in the *ssk2Δ ssk22Δ* background). Yeast cells were cotransformed with STE50-Myc together with STE11-GFP, and cells were subjected to a brief osmotic shock. STE11-GFP was precipitated with an anti-GFP antibody, and the presence of STE50-Myc in precipitates was detected with an anti-Myc monoclonal antibody. Although the levels of protein expression were much lower than in previous experiments, STE11-STE50 interaction was still evident. More important, the level of STE11-STE50 binding was not affected by osmotic shock (Fig. 8B). Thus, our results are consistent with a constitutive association between STE11 and STE50.

Another possible mechanism for MAPKKK activation is signal-induced dimerization of the kinase; for example, induced dimerization of the Raf MAPKKK leads to its activation (7, 12). If STE50 homodimerizes, as previously suggested by a two-hybrid analysis (3), it might mediate STE11 activation, for example, through autophosphorylation. Initially, we tried to demonstrate STE50 dimerization by two-hybrid analysis using pLexA-STE50 and pACT-STE50 constructs. However, because pLexA-STE50 gave a very strong signal by itself, it was not possible to demonstrate specific interaction between the two STE50 constructs (in contrast, the pACT-STE50 constructs used for Fig. 4 and 5 had very low background signals). To test STE50 dimerization more directly, coprecipitation analysis was performed. Yeast cells were cotransfected with expression plasmids for HA-STE50 and GST-STE50 and treated with a brief osmotic shock before cell lysis. The presence of HA-STE50 in the GST-STE50 precipitate was then probed. As shown in Fig. 8C, however, no coprecipitation of HA-STE50 and GST-STE50 was observed, whether cells were treated with a brief osmotic shock or not. Thus, we did not obtain evidence to support dimerization of STE50.

**Localization of STE11 and STE50 before and after osmotic stress.** If STE11 and STE50 are constitutively bound, they are expected to be localized similarly within cells. To test the localization of STE11 and STE50, we fused these proteins to GFP and expressed them from their own promoters, so that




FIG. 8. (A) STE50 binds to STE11 in a constitutive manner. Yeast cells were cotransformed with a plasmid expressing GST-STE50 fusion protein (or control GST) under the constitutive *P<sub>TEF1</sub>* promoter and another plasmid expressing HA-STE11 under the *P<sub>GAL1</sub>* promoter. Cells were grown in the presence of galactose, and samples were taken before (-) or 5 min after (+) the addition of NaCl to a final concentration of 0.4 M. GST proteins were precipitated by using glutathione-Sepharose beads as described in Materials and Methods, and HA-STE11 in precipitates was detected by immunoblotting with an anti-HA antibody. An antibody against GST was used to detect the GST fusion proteins. (B) Yeast cells were cotransformed with single-copy plasmids containing STE50-Myc and STE11-GFP expressed under their own promoters. Cells were grown in the presence of glucose and treated as for panel A, and STE50-Myc and STE11-GFP in precipitates were probed with anti-Myc and anti-GFP antibodies. (C) No homodimerization is observed for STE50. Yeast cells were cotransformed with a plasmid expressing GST-STE50 fusion protein (or control GST) under the constitutive *P<sub>TEF1</sub>* promoter and another plasmid expressing HA-STE50 under the *P<sub>GAL1</sub>* promoter. Cells were grown in the presence of galactose, and samples were treated and analyzed as for panel A.




FIG. 9. Similar intracellular localization patterns of STE50 and STE11. Distributions of STE11-GFP, STE50-GFP, and HOG1-GFP fusion proteins were analyzed by direct fluorescence microscopy. The GFP fusion proteins were expressed under their own promoters in single-copy plasmids. The host cells contain the respective null mutations (*ste11* $\Delta$ , *ste50* $\Delta$ , and *hog1* $\Delta$ ) to minimize any dose effect. Pictures were taken before (-) or 5 min after (+) the addition of NaCl to a final concentration of 0.4 M. Nuclear staining by DAPI (4',6-diamidino-2-phenylindole) showed that both STE11-GFP and STE50-GFP are excluded from nuclei (not shown). They are also excluded from vacuoles, as indicated by Nomarski microscopy.

they were expressed at physiological levels. Both STE11-GFP and STE50-GFP were functional, as indicated by complementation analysis. Under normal conditions (without osmotic stress), both STE11-GFP and STE50-GFP were found diffused throughout the cytoplasm but excluded from nuclei and vacuoles (Fig. 9). When cells were exposed to osmotic stress for 5

min, both proteins rearranged to a punctuate pattern. The expression level and localization of STE11-GFP are indistinguishable between wild-type and *ste50* mutant cells (data not shown). As a control to show that these changes are not observed with other proteins, we examined the localization of the HOG1-GFP fusion protein. Before osmotic shock, HOG1-

GFP was evenly distributed in both cytoplasm and nucleus (Fig. 9). Upon osmotic shock, HOG1-GFP translocated from the cytoplasm to the nucleus within 5 min. (HOG1 nuclear localization will be described fully elsewhere [8].) Therefore, these data also support the notion that STE50 and STE11 are constitutively bound to each other.

## DISCUSSION

The HOG1 MAP kinase cascade can be activated under osmotic stress by two different and independent upstream mechanisms; a two-component osmosensor (SLN1-YPD1-SSK1) activates the SSK2/SSK22 MAPKKs, and the transmembrane protein SHO1 mediates activation of the STE11 MAPKKK. The three MAPKKs (SSK2, SSK22, and STE11) can in turn independently activate the PBS2 MAPKK, the activator of the HOG1 MAPK. While the framework of the HOG1 pathway is now established, there are many mechanistic questions that remained unanswered, including how the transmembrane protein SHO1 activates STE11 MAPKKK. Previously we demonstrated that SHO1 binds directly to the PBS2 MAPKK (13) and that PBS2 also interacts with STE11 (16). However, because SHO1 does not interact directly with STE11 (16), it is difficult to imagine how the activation of STE11 is mediated by SHO1 alone. From these considerations, we suspected that an additional element or elements are required for the osmotic stress-induced activation of the STE11 MAPKKK. In this report, we described a genetic screening by which we identified STE50 as one such element. This genetic screening was quite exhaustive, since mutants in each complementation group were identified multiple times.

The results of this study demonstrate that STE50 is absolutely required for signal transduction in the SHO1-STE11 branch of the HOG pathway. We also demonstrated that STE50 binds to a specific binding site in the N terminus of STE11. The STE50-STE11 interaction is constitutive and is not affected by environmental osmotic conditions. It seems, therefore, as if STE50 is an integral and essential subunit of the STE11 kinase.

Previously, it was reported that overexpression of STE50 makes cells more sensitive to the presence of mating pheromone, while deletion of *STE50* reduced slightly mating efficiency (21, 28). In our strain background also, *ste50* mutations had a minimal effect on mating efficiency (Table 2). Therefore, STE50 seems to have only an accessory role, rather than an essential function, in pheromone signal transduction. The difference in levels of significance of STE50 in the two pathways is best illustrated by the different effects of *ste11Δ* and *ste50Δ* mutations in these pathways. Disruption of *STE11* completely abolishes signaling through both mating and osmosensing pathways, whereas *STE50* disruption has a significant effect only in the osmosensing pathway. This difference could be explained by several possible mechanisms. First, STE50 may have two different functions which are specific to each pathway. Alternatively, STE11 may be activated by several different mechanisms in the mating pathway, STE50 being only one of them. This would be consistent with the observation that deletion of *STE50* results in only a minor effect on the mating pathway. In contrast, activation of STE11 by osmotic stress may be completely dependent on a mechanism that involves STE50. Finally, it is also possible that the mating and the osmosensing pathway require different levels of the STE11 activity.

The binding of STE50 to STE11 is essential for the activation of STE11 by osmotic stress. It is unlikely, however, that STE50 binding alone activates STE11, because STE50 is constitutively bound to STE11, regardless of the environmental




FIG. 10. Schematic diagram of the similarities between STE50 and Ste4. *S. cerevisiae* STE50 interacts with the STE11 MAPKKK, and *S. pombe* Ste4 interacts with the Byr2 MAPKKK. The binding domains of these proteins are depicted. Amino acids 267 to 325 of STE50 have 32% identity to residues 204 to 262 of Ste4 (STE50-Ste4 Homology). The positions of the STE11 and Byr2 kinase domains, which are highly homologous to each other, are also shown.

osmotic conditions. It is more likely that the STE50-STE11 interaction is a prerequisite for STE11 to receive an upstream activating signal. STE50-N can bind STE11 but cannot complement the *ste50Δ* defect, indicating that STE50-C also has an important functional role. One possible role for the C-terminal region is to mediate STE50-STE50 dimerization and thus to indirectly promote STE11 dimerization. However, results of the coprecipitation experiment presented in this report do not support this hypothesis. Another possibility is that STE50-C mediates binding of STE11 to another upstream element that is directly responsible for the activation of STE11 activity. Our failure to identify mutants of such upstream elements suggests either that there is redundancy at that level or that such elements are essential. Attempts to identify STE50 interactors by two-hybrid screening have so far been unsuccessful. It is possible that the interaction of STE50 with the hypothetical upstream element occurs only after osmotic shock.

Comparison of the *S. pombe* Ste4 protein with STE50 gives some support to the latter model. Ste4 seems to serve a role similar to that of STE50 in signal transduction. Ste4 binds to the Byr2 MAPKKK, which is a homolog of STE11 and is involved in the signaling pathway for the mating pheromone or nitrogen starvation. The Ste4 binding domain (Ste4BD) in Byr2 and the Byr2 binding domain (Byr2BD) in Ste4 are both in their N-terminal regions (Fig. 10). Thus, the locations of the interaction domains are very similar to those of STE50-STE11 interaction. A further similarity of the Ste4-Byr2 interaction to the STE50-STE11 interaction is that the Ste4-Byr2 association is constitutive regardless of the presence or absence of mating pheromone or nitrogen starvation (25). Interestingly, however, there are no significant sequence similarities either between STE50BD and Ste4BD or between STE11BD and Byr2 BD: the sequence similarities between Ste4 and STE50 are limited to their C-terminal regions. In other words, their specificities but not the primary sequences, are similar. In contrast, the fact that the C termini of STE50 and Ste4 have some sequence identity (32% identity in a stretch of 59 amino acids) suggests that they may serve as interaction sites for a hypothetical upstream molecule.



## ACKNOWLEDGMENTS

We thank M. Takekawa, Q. Ge, and D. C. Raitt for comments on and critical reading of the manuscript; P. Silver and J. A. Kahana for plasmids and antibody against GFP; and P. Ferrigno for valuable suggestions.

This work was supported by NIH grants GM50909 and GM56699 to H. S. and by a postdoctoral fellowship from la Dirección General de Investigación Científica y Técnica of the Spanish Government to F.P.

## REFERENCES

- Adelberg, E. A., M. Mandel, and G. C. C. Chen. 1966. Optimal conditions for mutagenesis by *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine in *Escherichia coli* K12. *Biochem. Biophys. Res. Commun.* **18**:788–795.
- Albertyn, J., S. Hohmann, J. M. Thevelein, and B. A. Prior. 1994. *GPD1*, which encodes glycerol-3-phosphate dehydrogenase, is essential for growth under osmotic stress in *Saccharomyces cerevisiae*, and its expression is regulated by the high-osmolarity glycerol response pathway. *Mol. Cell. Biol.* **14**:4135–4144.
- Barr, M. M., L. Van Aelst, and M. Wigler. 1996. Identification of Ste4 as a potential regulator of Byr2 in the sexual response pathway of *Schizosaccharomyces pombe*. *Mol. Cell. Biol.* **16**:5597–5603.
- Boguslawski, G. 1992. *PBS2*, a yeast gene encoding a putative protein kinase, interacts with the *RAS2* pathway and affects osmotic sensitivity of *Saccharomyces cerevisiae*. *J. Gen. Microbiol.* **138**:2425–2432.
- Brewster, J. L., T. de Valoir, N. D. Dwyer, E. Winter, and M. C. Gustin. 1993. An osmosensing signal transduction pathway in yeast. *Science* **259**:1760–1763.
- Durfee, T., K. Becherer, P.-L. Chen, S.-H. Yeh, Y. Yang, A. E. Kilburn, W.-H. Lee, and S. J. Elledge. 1993. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. *Genes Dev.* **7**:555–569.
- Farrar, M. A., J. Alberola-Ila, and R. M. Perlmutter. 1996. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. *Nature* **383**:178–181.
- Ferrigno, P., F. Posas, H. Saito, and P. A. Silver. Submitted for publication.
- Foreman, P. K., and R. W. Davis. 1994. Cloning vectors for the synthesis of epitope-tagged, truncated and chimeric proteins in *Saccharomyces cerevisiae*. *Gene* **144**:63–68.
- Herskowitz, I. 1995. MAP kinase pathways in yeast: for mating and more. *Cell* **80**:187–197.
- Li, L., S. J. Elledge, C. A. Peterson, E. S. Bales, and R. J. Legerski. 1994. Specific association between the human DNA repair proteins XPA and ERCC1. *Proc. Natl. Acad. Sci. USA* **91**:5012–5016.
- Luo, Z., G. Tzivion, P. J. Belshaw, D. Vavvas, M. Marshall, and J. Avruch. 1996. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. *Nature* **383**:181–185.
- Maeda, T., M. Takekawa, and H. Saito. 1995. Activation of yeast PBS2 MAPKK by MAPKKs or by binding of an SH3-containing osmosensor. *Science* **269**:554–558.
- Maeda, T., S. M. Wurgler-Murphy, and H. Saito. 1994. A two-component system that regulates an osmosensing MAP kinase cascade in yeast. *Nature* **369**:242–245.
- Ota, I. M., and A. Varshavsky. 1993. A yeast protein similar to bacterial two-component regulators. *Science* **262**:566–569.
- Posas, F., and H. Saito. 1997. Osmotic activation of the HOG MAPK pathway via Ste11p MAPKKK: scaffold role of Pbs2p MAPKK. *Science* **276**:1702–1705.
- Posas, F., and H. Saito. 1998. Activation of the yeast SSK2 MAP kinase kinase by the SSK1 two-component response regulator. *EMBO J.* **17**:1385–1394.
- Posas, F., and H. Saito. Unpublished data.
- Posas, F., M. Takekawa, and H. Saito. 1998. Signal transduction by MAP kinase cascades in budding yeast. *Curr. Opin. Microbiol.* **1**:175–182.
- Posas, F., S. M. Wurgler-Murphy, T. Maeda, E. A. Witten, T. C. Thai, and H. Saito. 1996. Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the SLN1-YPD1-SSK1 “two-component” osmosensor. *Cell* **86**:865–875.
- Rad, M. R., G. Xu, and C. P. Hollenberg. 1992. *STE50*, a novel gene required for activation of conjugation at an early step in mating in *Saccharomyces cerevisiae*. *Mol. Gen. Genet.* **236**:145–154.
- Schmidt, A., M. N. Hall, and A. Koller. 1994. The FK506 resistance-conferring genes in *Saccharomyces cerevisiae*, *TAT1* and *TAT2*, encode amino acid permeases mediating tyrosine and tryptophan uptake. *Mol. Cell. Biol.* **14**:6597–6606.
- Sikorski, R. S., and J. D. Boeke. 1991. *In vitro* mutagenesis and plasmid shuffling: from cloned gene to mutant yeast. *Methods Enzymol.* **194**:302–318.
- Takekawa, M., F. Posas, and H. Saito. 1997. A human homolog of the yeast Ssk2/Ssk22 MAP kinase kinase kinases, MTK1, mediates stress-induced activation of the p38 and JNK pathways. *EMBO J.* **16**:4973–4982.
- Tu, H., M. Barr, D. L. Dong, and M. Wigler. 1997. Multiple regulatory domains on the Byr2 protein kinase. *Mol. Cell. Biol.* **17**:5876–5887.
- Vojtek, A. B., S. M. Hollenberg, and J. A. Cooper. 1993. Mammalian Ras interacts directly with the serine/threonine kinase Raf. *Cell* **74**:205–214.
- Waskiewicz, A. J., and J. A. Cooper. 1995. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. *Curr. Opin. Cell Biol.* **7**:798–805.
- Xu, G., G. Jansen, D. Y. Thomas, C. P. Hollenberg, and M. R. Rad. 1996. Ste50p sustains mating pheromone-induced signal transduction in the yeast *Saccharomyces cerevisiae*. *Mol. Microbiol.* **20**:773–783.